和鉑醫藥(02142.HK)與艾伯維就新冠抗體啟動臨牀試驗,強大創新能力獲國際驗證
格隆匯12月15日丨和鉑醫藥(02142.HK)今日宣佈由其與烏得勒支大學共同授權艾伯維的針對COVID-19和相關冠狀病毒預防和治療的全人源中和抗體ABBV- 47D11,已開展一期臨牀試驗。艾伯維將先行在美國開展該臨牀研究項目,並擴展至歐洲地區。和鉑醫藥的H2L2全人源轉基因小鼠平台能夠快速發現和開發有效候選藥物,其中ABBV-47D11成為此次理想的候選藥物。該抗體靶向SARS-CoV-2的保守區域,迄今為止通過合作的臨牀前研究表明,針對該靶點的抗體對當下的疫情具有良好的治療潛力,包括一系列潛在逃逸突變。在臨牀前研究中,該抗體表現出阻斷SARS-CoV-2以及SARS-CoV-1感染的潛力。根據授權協議,艾伯維將為該抗體的權益向和鉑醫藥及烏得勒支大學支付一次性權益轉讓費與特許開發、監管和銷售的階段性費用,以及商業銷售淨額的分級使用費。和鉑醫藥通過其享有全球專利的抗體發現平台開展包括該項目在內的諸多對外授權共同發現/開發項目,該項目的順利進展體現了和鉑醫藥強大的創新研發能力以及國際領先的行業夥伴對和鉑醫藥抗體發現平台的高度認可。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.